Twenty-eight days repeated oral dose toxicity study of gemifloxacin in Wistar albino rats

Regulatory Toxicology and Pharmacology

Volumn 58, Issue 2, 2010, Pages 196-207

  Roy, Bikash ^a   Sarkar, Amlan Kanti ^a   Sengupta, Pinaki ^a   Dey, Goutam ^a   Das, Anjan ^a   Pal, Tapan Kumar ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Fluroquinolones; Gemifloxacin; Repeated oral dose; Subchronic toxicity; Wistar albino rats

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; GEMIFLOXACIN; GLUCOSE;

ACHILLES TENDON; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BODY WEIGHT; CHRONIC HEPATITIS; CHRONIC TOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; FLUID INTAKE; FOOD INTAKE; GASTRITIS; HEMATOLOGY; HISTOPATHOLOGY; LEUKOCYTE; LIVER WEIGHT; MALE; MICROSCOPY; MORTALITY; NONHUMAN; OPHTHALMOSCOPY; ORGAN WEIGHT; PHOTOTOXICITY; PRIORITY JOURNAL; RAT; STOMACH MUCOSA INJURY; SYNOVIAL FLUID; URINALYSIS; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG-INDUCED LIVER INJURY; FEMALE; FLUOROQUINOLONES; GASTRITIS; MALE; NAPHTHYRIDINES; RATS; RATS, WISTAR; SEX FACTORS; TOXICITY TESTS;

RATTUS;

EID: 77957357263     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.05.008     Document Type: Article

References (34)

1. Allen A., Bygate E., Vousden M., Oliver S., Johnson M., Ward C., Cheon A.J., Choo Y.S., Kim I.C. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. Antimicrob. Agents Chemother. 2001, 45:540-545.
2. Bae C.S., Oh D.M., Bae J.G., Kim J.C., Kim S.H., Kim S.G., Jeong M.J., Kim Y.S., Lim S.C. Ultrastructural changes of the gemifloxacin on Achilles tendon in immature rats: comparison with those of ciproxacin and ofloxacin. BCPT 2006, 98(4):406-410.
3. Ball P. Quinolone generations: natural history or natural selection? J. Antimicrob. Chemother. 2000, 46:17-24.
4. Ball P. Adverse drug reactions: implications for the development of fluroquinolones. J. Antimicrob. Chemother. 2003, 51(Suppl. S1):21-27.
5. Berry V., Page R., Satterfield J., Singley C., Straub R., Woodnutt G. Comparative efficacy of gemifloxacin in a rat model of respiratory tract infection. J. Antimicrob. Chemother. 2000, 45:79-85.
6. Blasi F., Tarsia P., Aliberti S., Santus P.A., Allegra L. Highlights on the appropriate use of fluroquinolones in respiratory tract infections. Pulm. Pharmacol. Ther. 2006, 19:11-19.
7. Boorman G.A., Eustis S.L., Elwell M.R., Montgomery C.A., Mackenzie W.F. Pathology of the Fischer Rat. Reference and Atlas 1990, Academic Press, San Diego.
8. Cormican M.G., Jones R.N. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob. Agents Chemother. 1997, 41:204-211.
9. Duffus J.F. World Health Organization, Geneva, 1979, Agreed terms on health effects evaluation and risk and hazard assessment of environmental agents. Internal report of a working group, (EHE/EHC/79.19) in glossary for chemists of terms used in toxicology. Pure Appl. Chem. 1993, 65:2003-2122.
10. Eliseo P., Enrique B.G., Agustin M., Jose R., Paloma V. Synovial fluid analysis for diagnosis of intercritical gout. Ann. Intern. Med. 1999, 131:756-759.
11. Erwin M.E., Jones R.N. Studies to establish quality control ranges for SB-265805 (LB20304) when using antimicrobial susceptibility test methods. Quality control study group. J. Clin. Microbiol. 1999, 37:279-280.
12. Greaves P. Histopathology of Preclinical Studies: Interpretation and Relevance in Drug Evaluation 1990, Elsevier, New York.
13. Guzman A., Garcia C., Demestre I. Subchronic toxicity of the new quinolone antibacterial agent irloxacin in Beagle dogs. Arzneim.-Forsch./Drug Res. 2000, 50:485-494.
14. Hannan P., Woodnutt G. In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas. Antimicrob. Agents Chemother. 2000, 45:367-369.
15. Haschek W.M., Rousseaux C.G. Fundamentals of Toxicologic Pathology 1998, Academic Press, San Diego.
16. Hayashi N., Nakata Y., Yazaki A. New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones with various substituents at position 1. Antimicrob. Agents Chemother. 2004, 48(3):799-803.
17. Hooper D.C., Wolfson J.S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in human. Antimicrob. Agents Chemother. 1985, 28:716-721.
18. Hussy P., Maass G., Tmmler B., Grosse F., Schomburg U. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase a primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob. Agents Chemother. 1986, 29:1073-1108.
19. Johnson D.M., Jones R.N., Erwin M.E. Anti-streptococcal activity of SB-265805 (LB20304) a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines. Diagn. Microbiol. Infect. Dis. 1999, 33:87-91.
20. Kang B.H., Son H.Y., Ha C.S., Lee H.S., Song S.W. Reference values of hematology and serum chemistry in Ktc: Sprague-Dawley rats. Kor. J. Anim. Sci. 1995, 11:141-145.
21. Kim J.C., Kang B.H., Shin C.C., Kim Y.B., Lee H.S., Kim C.Y., Han J., Kim K.S., Chung D.W., Chung M.K. Subchronic toxicity of plant sterol esters administered by gavage to Sprague-Dawley rats. Food Chem. Toxicol. 2002, 40:1369-1380.
22. Lu G.C., She J.H., Jiang H., Li Z.Y., Yuan B.J. Sixty-day repeated dose toxicity of sinafloxacin in rat and dogs. Food Chem. Toxicol. 2008, 46:575-580.
23. Marutani K., Matsumoto M., Otabe Y., Nagamuta M., Tanaka K., Miyoshi A., Hasegawa T., Nagano H., Matsubara S., Kamide R., Yokota T., Matsumoto F., Ueda Y. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light. Antimicrob. Agents Chemother. 1993, 37:2217-2223.
24. OECD (Organization for Economic Co-operation and Development), 1995. Guideline for the Testing of Chemicals. Guideline 407: Repeated Dose 28-Day Oral Toxicity Study in Rodents (Adopted 27.07.1995).
25. Phelps P., Steele A.D., McCarty D.J. Compensated polarized light microscopy. Identification of crystals in synovial fluids from gout and pseudogout. JAMA 1968, 203:508-512.
26. Ramji J.V., Austin N.E., Boyle G.W., Chalker M.H., Duncan G., Fairless A.J., Hollis F.J., McDonnell P.C. The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs. Drug Metab. Dispos. 2001, 29:435-442.
27. Shimada J., Hori S. Adverse effects of fluoroquinolones. Prog. Drug Res. 1992, 38:133-143.
28. US Food and Drug Administration, 1978. Good laboratory practice Regulations 21 CFR Part 58. Federal Register 22 December 1979 and subsequent amendments.
29. von Keutz E., Schluter G. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J. Antimicrob. Chemother. 1999, 43(Suppl. B):91-100.
30. Vousden M., Ferguson J., Richards J., Bird N., Allen A. Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin. Chemotherapy 1999, 45:512-520.
31. Wagai N., Tawara K. Quinolone antibacterial-agent-induced cutaneous phototoxicity: ear swelling reactions in Balb/c mice. Toxicol. Lett. 1991, 58:215-223.
32. Wagai N., Yamaguchi F., Sekiguchi M., Tawara K. Phototoxic potential of quinolone antibacterial agents in Balb/c mice. Toxicol. Lett. 1990, 54:299-308.
33. Wolford S.T., Schroer R.A., Gohs F.X., Gallo P.P., Brodeck M., Falk H.B., Ruhren F.R. Reference range data base for serum chemistry and hematology values in laboratory animals. J. Toxicol. Environ. Health 1986, 18:161-188.
34. Wright D.H., Brown G.H., Peteson M.L., Rotschafer J.C. Application of fluroquinolone pharmacodynamics. J. Antimicrob. Chemother. 2000, 46:669-683.